The Importance of Glucagon-Like Peptide-2 (GLP-2)in Mesenteric Bloodflow in Humans
|ClinicalTrials.gov Identifier: NCT00273000|
Recruitment Status : Unknown
Verified October 2005 by Glostrup University Hospital, Copenhagen.
Recruitment status was: Recruiting
First Posted : January 9, 2006
Last Update Posted : September 11, 2006
|Condition or disease||Intervention/treatment|
The investigation will include 10 testpersons.
It will be a 2 fase study over 2 days.
day 1: The testperson will meet fasting, and take in a standard liquid meal, after this the bloodflow in a mesenteric artery will be measured by use of ultrasonic technique. Bloodsamples will be taken regular in a total wolumne of 200 ml.
day 2:The testperson will meet fasting, there wil be administered intraveneous GLP-2 in 3 increasing doses over 3 x 45 min.and one subcutaneous dose. During this the bloodflow in a mesenteric artery will be measured by use of ultrasonic technique. Bloodsamples will be taken regular in a total wolumne of 200 ml.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Health Services Research|
|Official Title:||The Importance of Glucagon-Like Peptide-2 (GLP-2)in Mesenteric Bloodflow in Humans|
|Study Start Date :||January 2006|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00273000
|Contact: Lasse Bremholm Hansen, MDemail@example.com|
|Copenhagen, Copenhagen City, Denmark, 2100|
|Contact: Lasse Bremholm Hansen, MD 004560927874 firstname.lastname@example.org|
|Sub-Investigator: Mads Hornum, MD|
|Principal Investigator:||Mads Hornum, MD||Glostrup University Hospital, Copenhagen|